INmune Bio Joins 26-Firm Alliance to Safeguard U.S. Biotech Leadership
Event summary
- INmune Bio named a founding member of the American Biotech Innovation Alliance (ABIA) on May 13, 2026.
- ABIA launched with 26 founding companies to develop a national strategy for U.S. biotech leadership.
- Alliance aims to address manufacturing capacity, early-stage research investment, regulatory flexibility, and workforce development.
- INmune Bio joins other biotech leaders to shape ABIA's 'Vision 2030' strategy.
The big picture
The launch of the American Biotech Innovation Alliance (ABIA) marks a critical response to the shifting landscape of the U.S. biotech sector. With global competition and market volatility threatening to erode the U.S.'s historic advantage in medical discovery, the ABIA aims to build strategic alignment within the industry. The alliance's focus on manufacturing capacity, early-stage research investment, regulatory flexibility, and workforce development highlights the urgent need for proactive coordination and strategic capital formation to sustain U.S. leadership in biotech innovation.
What we're watching
- Regulatory Flexibility
- How ABIA's push for regulatory flexibility will impact mid-size and emerging biotech innovators.
- Strategic Alignment
- Whether the ABIA can successfully align industry leaders to draft a cohesive framework for policymakers.
- Global Competition
- The pace at which the U.S. biotech sector can address global competition and offshored supply chains.
Related topics